Merck’s FDA approval of KEYTRUDA QLEX™ for subcutaneous use marks a significant advancement in the treatment of solid tumors, enhancing patient convenience and potentially improving treatment adherence. This innovation not only demonstrates Merck’s commitment to oncology but also reinforces the growing trend of simplifying administration methods in cancer therapies.
RAHWAY, N.J.–(BUSINESS WIRE)—- $MRK #MRK–Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced that the U.S. Food and Drug Administration (FDA) has approved KEYTRUDA QLEX™ (pembrolizumab and berahyaluronidase alfa-pmph) injection for subcutaneous administration in adults across most solid tumor indications for KEYTRUDA® (pembrolizumab). Berahyaluronidase alfa is a variant of human hyaluronidase developed and manufactured by Alteogen Inc. KEYTRUDA QLEX must be administer
Source: Original Press Release
